According to the press release by AstraZeneca on February 19th, the use of Tagrisso (osimertinib) after chemoradiotherapy (CRT) in patients with unresectable, stage III EGFR-mutated non-small-cell lung cancer (NSCLC) significantly improved progression-free survival (PFS) compared to placebo. This finding is based on the Phase III LAURA study that included 216 patients whose disease had not progressed following definitive platinum‑based CRT. The patients were randomised to receive either once daily osimertinib or placebo after chemoradiotherapy. The overall survival data is still maturing.

This news brings new hope for the patients with stage III EGFR-mutated lung cancer and it will be interesting to see the maturing overall survival data.

READ THE ARTICLE – https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-improved-pfs-in-stage-iii-lung-cancer.html